Re: Phase I Clinical Trial of a Selective Inhibitor of CYP17, Abiraterone Acetate, Confirms That Castration-Resistant Prostate Cancer Commonly Remains Hormone Driven

Faculty Opinions recommendation of Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.1118816.793494158 ◽

2014 ◽

Author(s):

Thomas Flaig

Keyword(s):

Prostate Cancer ◽

Clinical Trial ◽

Phase I ◽

Abiraterone Acetate ◽

Selective Inhibitor ◽

Phase I Clinical Trial ◽

Re: Phase I Clinical Trial of a Selective Inhibitor of CYP17, Abiraterone Acetate, Confirms that Castration-Resistant Prostate Cancer Commonly Remains Hormone Driven

European Urology ◽

10.1016/j.eururo.2008.09.035 ◽

2009 ◽

Vol 55 (1) ◽

pp. 248

Author(s):

Mario A. Eisenberger

Keyword(s):

Prostate Cancer ◽

Clinical Trial ◽

Phase I ◽

Abiraterone Acetate ◽

Selective Inhibitor ◽

Phase I Clinical Trial ◽

Faculty Opinions recommendation of Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.1118816.574906 ◽

2008 ◽

Author(s):

John Amory

Keyword(s):

Prostate Cancer ◽

Clinical Trial ◽

Phase I ◽

Abiraterone Acetate ◽

Selective Inhibitor ◽

Phase I Clinical Trial ◽

Re: Phase I Clinical Trial of a Selective Inhibitor of CYP17, Abiraterone Acetate, Confirms that Castration-Resistant Prostrate Cancer Commonly Remains Hormone Driven

European Urology ◽

10.1016/j.eururo.2009.04.017 ◽

2009 ◽

Vol 56 (1) ◽

pp. 220 ◽

Cited By ~ 1

Author(s):

Nicholas J. Vogelzang

Keyword(s):

Clinical Trial ◽

Phase I ◽

Abiraterone Acetate ◽

Selective Inhibitor ◽

Phase I Clinical Trial ◽

Prostrate Cancer ◽

Preclinical profile and phase I clinical trial of a novel androgen receptor antagonist GT0918 in castration-resistant prostate cancer

European Journal of Cancer ◽

10.1016/j.ejca.2020.04.013 ◽

2020 ◽

Vol 134 ◽

pp. 29-40 ◽

Cited By ~ 1

Author(s):

Tie Zhou ◽

Weidong Xu ◽

Wei Zhang ◽

Ye Sun ◽

Honghua Yan ◽

...

Keyword(s):

Prostate Cancer ◽

Clinical Trial ◽

Androgen Receptor ◽

Phase I ◽

Receptor Antagonist ◽

Phase I Clinical Trial ◽

Androgen Receptor Antagonist ◽

Phase I clinical trial of cell division associated 1 (CDCA1) peptide vaccination for castration resistant prostate cancer

Cancer Science ◽

10.1111/cas.13278 ◽

2017 ◽

Vol 108 (7) ◽

pp. 1452-1457 ◽

Cited By ~ 13

Author(s):

Wataru Obara ◽

Fuminori Sato ◽

Kazuyoshi Takeda ◽

Renpei Kato ◽

Yoichiro Kato ◽

...

Keyword(s):

Prostate Cancer ◽

Clinical Trial ◽

Cell Division ◽

Phase I ◽

Phase I Clinical Trial ◽

Peptide Vaccination ◽

1275 PHASE I CLINICAL TRIAL OF NOVEL CDCA1 DERIVED EPITOPE PEPTIDE VACCINE THERAPY FOR CASTRATION-RESISTANT PROSTATE CANCER

The Journal of Urology ◽

10.1016/j.juro.2011.02.961 ◽

2011 ◽

Vol 185 (4S) ◽

Cited By ~ 1

Author(s):

Wataru Obara ◽

Fuminori Sato ◽

Koji Yoshida ◽

Takuya Tsunoda ◽

Kazuhiro Iwasaki ◽

...

Keyword(s):

Prostate Cancer ◽

Clinical Trial ◽

Phase I ◽

Peptide Vaccine ◽

Phase I Clinical Trial ◽

Vaccine Therapy ◽

Epitope Peptide ◽

ProCAID: a phase I clinical trial to combine the AKT inhibitor AZD5363 with docetaxel and prednisolone chemotherapy for metastatic castration resistant prostate cancer

Investigational New Drugs ◽

10.1007/s10637-017-0433-4 ◽

2017 ◽

Vol 35 (5) ◽

pp. 599-607 ◽

Cited By ~ 18

Author(s):

Simon J. Crabb ◽

Alison J. Birtle ◽

Karen Martin ◽

Nichola Downs ◽

Ian Ratcliffe ◽

...

Keyword(s):

Prostate Cancer ◽

Clinical Trial ◽

Phase I ◽

Phase I Clinical Trial ◽

Akt Inhibitor ◽

Sargramostim (GM-CSF) and lenalidomide in castration-resistant prostate cancer (CRPC): Results from a phase I-II clinical trial

Urologic Oncology Seminars and Original Investigations ◽

10.1016/j.urolonc.2012.12.004 ◽

2014 ◽

Vol 32 (1) ◽

pp. 33.e11-33.e17 ◽

Cited By ~ 10

Author(s):

Jorge A. Garcia ◽

Paul Elson ◽

Allison Tyler ◽

Pierre Triozzi ◽

Robert Dreicer

Keyword(s):

Prostate Cancer ◽

Clinical Trial ◽

Phase I ◽

Gm Csf ◽

Abstract 3720: Encouraging activity of bicalutamide and everolimus in castration-resistant prostate cancer (CRPC): Early results from a phase I/II clinical trial

10.1158/1538-7445.am10-3720 ◽

2010 ◽

Author(s):

Hongyong Zhang ◽

Yu Wang ◽

Paramita Ghosh ◽

Primo N. Lara ◽

Patricia Pasquinelli ◽

...

Keyword(s):

Prostate Cancer ◽

Clinical Trial ◽

Phase I ◽

Castration Resistant ◽

Early Results